About 5-hydroxytryptamine receptor 2C
5-hydroxytryptamine receptor 2C (HTR2C) is a protein
from Homo sapiens identified by UniProt accession
P28335, 458 residues long.
MolForge cross-references it against 0 known binders and
289 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 2C |
| UniProt accession | P28335 |
| Gene | HTR2C |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (289)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.61
- bipolar disorder · score 0.61
- unipolar depression · score 0.61
- autism · score 0.61
- schizoaffective disorder · score 0.60
- major depressive disorder · score 0.60
- depressive disorder · score 0.60
- bipolar I disorder · score 0.60
- aggressive behavior · score 0.60
- Agitation · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P28335-F1 | alphafold | PREDICTED | 73.56 | — |
Amino-acid sequence (458 residues)
MVNLRNAVHS FLVHLIGLLV WQSDISVSPV AAIVTDIFNT SDGGRFKFPD GVQNWPALSI VIIIIMTIGG NILVIMAVSM EKKLHNATNY FLMSLAIADM LVGLLVMPLS LLAILYDYVW PLPRYLCPVW ISLDVLFSTA SIMHLCAISL DRYVAIRNPI EHSRFNSRTK AIMKIAIVWA ISIGVSVPIP VIGLRDEEKV FVNNTTCVLN DPNFVLIGSF VAFFIPLTIM VITYCLTIYV LRRQALMLLH GHTEEPPGLS LDFLKCCKRN TAEEENSANP NQDQNARRRK KKERRPRGTM QAINNERKAS KVLGIVFFVF LIMWCPFFIT NILSVLCEKS CNQKLMEKLL NVFVWIGYVC SGINPLVYTL FNKIYRRAFS NYLRCNYKVE KKPPVRQIPR VAATALSGRE LNVNIYRHTN EPVIEKASDN EPGIEMQVEN LELPVNPSSV VSERISSV
Explore 5-hydroxytryptamine receptor 2C with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets